<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061931</url>
  </required_header>
  <id_info>
    <org_study_id>MACPAF</org_study_id>
    <secondary_id>4-087-08</secondary_id>
    <nct_id>NCT01061931</nct_id>
  </id_info>
  <brief_title>Mesh Ablator Versus Cryoballoon Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrillation</brief_title>
  <acronym>MACPAF</acronym>
  <official_title>HD Mesh Ablator Versus Cryoballoon Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrillation - Efficiency and Safety of PV Ablation Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective randomized single-center trial is to compare efficiency and
      safety of two pulmonary vein ablation systems in patients with symptomatic paroxysmal atrial
      fibrillation using the Arctic Front® versus the HD Mesh Ablator® catheter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:

      • Efficacy of pulmonary vein isolation defined by achieving an exit block for all pulmonary
      veins per patient.

      Secondary objectives:

        -  Detecting (silent) cerebral thromboembolism using neuro(psychological) tests and brain
           MRI prior and within 2 days after PV ablation.

        -  Detecting (silent) cerebral thromboembolism using neuro(psychological) tests and brain
           MRI within 6 months after PV ablation.

        -  Determination of spontaneous recurrence rate of atrial fibrillation using a
           subcutaneously implanted loop recorder (Reveal XT®).

        -  Characterization of non-neurological major complications (death, atrial-esophageal
           fistula, pulmonary vein stenosis, pericardial tamponade)

        -  Rate of iatrogenic interatrial septal defects after transseptal puncture for PV
           ablation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    reason
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of pulmonary vein isolation defined by achieving an exit block for all pulmonary veins per patient</measure>
    <time_frame>During ablation procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detecting (silent) cerebral thromboembolism using neuro(psychological) tests and brain MRI</measure>
    <time_frame>within 2 days after catheter ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detecting (silent) cerebral thromboembolism using neuro(psychological) tests and brain MRI</measure>
    <time_frame>6 months after catheter ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of spontaneous recurrence rate of atrial fibrillation using a subcutaneously implanted loop recorder (Reveal XT®)</measure>
    <time_frame>1 year after catheter ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of non-neurologic major complications (death, atrial-esophageal fistula, pulmonary vein stenosis, pericardial tamponade)</measure>
    <time_frame>within 1 month after catheter ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of iatrogenic interatrial septal defects after transseptal puncture for left-sided atrial catheter ablation</measure>
    <time_frame>1 year after catheter ablation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Symptomatic Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Arctic Front® catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HD Mesh Ablator® catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Arctic Front® catheter vs. HD Mesh Ablator® catheter</intervention_name>
    <description>Pulmonary vein ablation in patients with symptomatic paroxysmal atrial fibrillation using the Arctic Front® catheter versus the HD Mesh Ablator® catheter</description>
    <arm_group_label>Arctic Front® catheter</arm_group_label>
    <arm_group_label>HD Mesh Ablator® catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ECG-documented symptomatic paroxysmal atrial fibrillation and at least
             one ineffective antiarrhythmic drug treatment

        Exclusion Criteria:

          -  Previous ablation procedure for atrial fibrillation or cardiac surgery within 3 months

          -  Left atrial diameter &gt; 50mm or ejection fraction &lt; 35%

          -  Instable coronary artery disease or clinically relevant cardiac valve insufficiency

          -  Hyperthyroidism, pregnancy or lactation; coumadin or heparin intolerance

          -  Concomitant disease with expected lifespan &lt; 2 years

          -  Contraindications for MRI or acute cerebral infarction detected by brain MRI
             immediately (&lt; 24 hours) before catheter ablation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Schirdewan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Charité - University Medicine Berlin, Germany.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jochen B Fiebach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Stroke Research Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité, University Medicine Berlin, Campus Benjamin Franklin, Hindenburgdamm 30</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2010</study_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Jochen B. Fiebach</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>left-sided atrial catheter ablation</keyword>
  <keyword>paroxysmal atrial fibrillation</keyword>
  <keyword>cryoballoon technique</keyword>
  <keyword>mesh ablator catheter</keyword>
  <keyword>stroke</keyword>
  <keyword>silent stroke</keyword>
  <keyword>major complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

